Table 2.

Clinical outcome stratified by early metabolic response

A. Histologic assessment of residual disease after completion of Bev + Pac
Metabolic response
Histologic responseResponderNonresponderP valuea
pNR020.02
pPR85
pCR30
Continuation of chemotherapy without surgery73
Total1810
B. Clinical assessment after completion of Bev + PTX
Metabolic response
Clinical responseResponderNonresponderP valuea
PD020.01
SD44
PR124
CR20
Total1810
  • Abbreviations: Bev, bevacizumab; Pac, paclitaxel; PD, progressive disease; pNR, pathologic no response; pPR, pathologic partial response; PR, partial response; SD, stable disease.

  • aχ2 test.